Fountain Therapeutics
Mission Bay
San Francisco
CA
94107
United States
9 articles with Fountain Therapeutics
-
Fountain Therapeutics Congratulates Co-Founder and Executive Chairman Thomas Rando, M.D., Ph.D., for Prestigious NOMIS Distinguished Scientist Award
10/5/2022
Fountain Therapeutics announced that Thomas Rando, M.D., Ph.D., co-founder and executive chairman of Fountain, is being honored in a ceremony held in Zurich to receive the prestigious NOMIS Distinguished Scientist Award.
-
BioSpace Movers & Shakers, Jan. 21
1/21/2022
Biopharma and life sciences companies made numerous appointments this week to boards and executive teams. These Movers & Shakers will position the companies for future growth. -
Fountain Therapeutics Announces Appointment of Anupama Hoey as Chief Business Officer
1/18/2022
Fountain Therapeutics today announced the appointment of Anupama Hoey as chief business officer (CBO) effective January 17 th , 2022.
-
Fountain Therapeutics Announces $15 Million Series A-2 Financing
11/18/2021
Fountain Therapeutics today announced a $15 million Series A-2 financing, which brings its total Series A funding to $26 million.
-
The life sciences is always a frenetic sector when it comes to mergers & acquisitions, initial public offerings (IPOs) and Series A announcements (not to mention B and C rounds). But during the second quarter of 2021, these companies were especially busy bees – all positive signs that the industr...
-
Fountain Therapeutics to Present at 2nd Annual LifeSci Partners Private Company Summer Symposium
7/19/2021
Fountain Therapeutics today announced that William Greene, M.D., chief executive officer of Fountain, will present a corporate overview at the 2nd Annual LifeSci Partners Private Company Summer Symposium to be held July 21-23, 2021.
-
Fountain Therapeutics Appoints William L. Greene, M.D. Chief Executive Officer
4/26/2021
Fountain Therapeutics, a biopharmaceutical company building a pipeline of therapeutics to treat age-related diseases by reversing cellular age, today announced the appointment of William L. Greene, M.D. as the company’s chief executive officer, effective April 26, 2021.
-
Fountain Therapeutics Moves Corporate Headquarters to Lilly Gateway Labs in South San Francisco
9/9/2020
Fountain Therapeutics (“Fountain”), a biopharmaceutical company building a pipeline of therapeutics to treat age-related diseases by reversing cellular age, today announced it has moved its corporate headquarters to Lilly Gateway Labs in South San Francisco upon selection by Eli Lilly and Company.
-
Fountain Therapeutics Closes $6 Million Series A-1 Financing
5/19/2020
Closing brings total Series A financing sum to $11 million Funds to support expansion of team, technology platform and in vivo preclinical drug testing